Results 161 to 170 of about 2,223,665 (257)

Image_2_IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.tif

IntroductionSorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic.
Chidan Wan (144282), Junzhang Chen (12427704), Hui Li (32376), Xiong Cai (140594), Shiran Sun (14095587)   +4 more
core   +1 more source

DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC

Advanced Science, Volume 13, Issue 52, 18 September 2026.
This non‑enzymatic function of DHODH drives sunitinib resistance by competing with TRIM37 to block TRIM28 ubiquitination, thereby stabilizing TRIM28 and activating VEGFA transcription. Disrupting the DHODH–TRIM28 interaction with lisaftoclax restores drug sensitivity.
Shijie Qian, Shihang Pu, Zhipeng Xu, Yiheng Ding, Ling Jin, Baochao Li, Qi Li, Xiaohai Xi, Zengjun Wang, Jiajun Xing, Aiming Xu   +10 more
wiley   +1 more source

Precision Oncology via Radiotherapy‐Triggered Drug Delivery: Mechanisms, Molecular Engineering, and Clinical Translation

Advanced Science, Volume 13, Issue 52, 18 September 2026.
This review redefines radiotherapy‐triggered drug delivery systems through structural disassembly and molecular actuation, proposing a translation‐oriented framework for dose‐correlated activation to advance clinically integrated precision oncology. ABSTRACT Radiotherapy‐triggered drug delivery systems (RDDS) promise to integrate the spatial precision ...
Jianv Jiang, Tanfeng Zhang, Junliang Dong, Wenjing Sun   +3 more
wiley   +1 more source

HIF1α-KLF4 signaling dictates extra-erythrocyte expression of hemoglobin conferring sorafenib resistance in hepatocellular carcinoma. [PDF]

Signal Transduct Target Ther
Zhang B, Liu F, Gao X, Zhu Y, Chen T, Hao J, Wei Y, Sun Z, Yang R, Yang Y, Ren H, Li Y, Yu C, Ren T, Huang Y, Jiang H, Melino G, Ma L, Huang H, Sun Q.   +19 more
europepmc   +1 more source

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management

American Journal of Hematology, Volume 101, Issue 9, Page 2393-2411, September 2026.
ABSTRACT Disease Overview The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
Guillermo Garcia‐Manero
wiley   +1 more source

In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

, 2016
Shaomei Yang,1 Bo Zhang,1 Xiaowei Gong,2 Tianqi Wang,1 Yongjun Liu,1 Na Zhang1 1Department of Pharmaceutics, College of Pharmacy, Shandong University, 2Shandong Provincial Key Laboratory of Neuroprotective Drug, Jinan, Shandong Province, People’s ...
Liu Y, Wang T, Zhang N, Yang S, Zhang B, Gong X   +5 more
core  

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

Brain and Behavior, Volume 16, Issue 9, September 2026.
Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, driven by abnormal signaling pathways that promote growth and resistance to treatment. Conventional therapies are inadequate, highlighting the need for novel multitargeted approaches.
Mehrukh Zehravi, Md Abul Hassan, Md. Al Amin, Sherouk Hussein Sweilam, Jeetendra Kumar Gupta, Ramenani Hari Babu, Pericharla Venkata Narasimha Raju, Krishna Vamsi Kandimalla, Phanindra Erukulla, Patibandla Jahnavi, Rajeshwar Vodeti, Abdul Ajeed Mohathasim Billah, Safia Obaidur Rab, Sharuk L. Khan   +13 more
wiley   +1 more source

AURKA suppresses NCOA4-mediated ferritinophagy to enhance sorafenib resistance in hepatocellular carcinoma. [PDF]

Cell Death Dis
Zhu W, Li Y, Li Z, Huang J, Zhu Q, Qiu H, Chen E, Sun H, Shi D, Chen M, Xie W, Deng W.   +11 more
europepmc   +1 more source

Table_1_IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.docx

IntroductionSorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic.
Chidan Wan (144282), Junzhang Chen (12427704), Hui Li (32376), Xiong Cai (140594), Shiran Sun (14095587)   +4 more
core   +1 more source

Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3‐Rearranged Renal Cell Carcinoma: A Multicenter Real‐World Study

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background TFE3‐rearranged renal cell carcinoma (TFE3‐rRCC) is uncommon and encompasses biologically diverse tumors, while evidence to guide systemic treatment remains sparse. We examined clinical outcomes, treatment patterns, and molecular features in a multicenter real‐world cohort.
Shuxuan Zhu, Siqi Zhou, Xi Tian, Jun Wang, Ze Wang, Jun Jiang, Qiuli Liu, Xin Gou, Xiang Zhou, Jun Gu, Jianfeng Yang, Jianhui Chen, Shushang Chen, Wenfeng Wang, Aihetaimujiang Anwaier, Kun Chang, Yuanyuan Qu, James Brugarolas, Wenhao Xu, Hailiang Zhang, Dingwei Ye   +20 more
wiley   +1 more source